当前位置：
X-MOL 学术
›
Int. J. Neuropsychopharmacol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
International Journal of Neuropsychopharmacology ( IF 4.5 ) Pub Date : 2020-08-29 , DOI: 10.1093/ijnp/pyaa068 Dawn F Ionescu 1 , Dong-Jing Fu 2 , Xin Qiu 3 , Rosanne Lane 4 , Pilar Lim 4 , Siegfried Kasper 5 , David Hough 2 , Wayne C Drevets 1 , Husseini Manji 2 , Carla M Canuso 2
International Journal of Neuropsychopharmacology ( IF 4.5 ) Pub Date : 2020-08-29 , DOI: 10.1093/ijnp/pyaa068 Dawn F Ionescu 1 , Dong-Jing Fu 2 , Xin Qiu 3 , Rosanne Lane 4 , Pilar Lim 4 , Siegfried Kasper 5 , David Hough 2 , Wayne C Drevets 1 , Husseini Manji 2 , Carla M Canuso 2
Affiliation
Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment.
中文翻译：
Esketamine 鼻喷雾剂用于快速减轻有主动自杀意念的重度抑郁症患者的抑郁症状：3 期、双盲、随机研究 (ASPIRE II) 的结果。
有主动自杀意念的重度抑郁症 (MDD) 患者需要立即治疗。
更新日期：2020-08-30
中文翻译：
Esketamine 鼻喷雾剂用于快速减轻有主动自杀意念的重度抑郁症患者的抑郁症状：3 期、双盲、随机研究 (ASPIRE II) 的结果。
有主动自杀意念的重度抑郁症 (MDD) 患者需要立即治疗。
京公网安备 11010802027423号